Our broad expertise, end-to-end services and ability to begin immediate collaboration with government, commercial and academic partners in more than 60 countries make us uniquely positioned to support the COVID-19 response. We address emerging pandemics, epidemics and outbreaks with expertise that supports health and research efforts globally. We are experienced in addressing the complex aspects of infectious diseases — from infection prevention and control to clinical research on diagnostics, vaccines and treatment.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
Since 1976, Ebola virus disease outbreaks have primarily occurred in eleven countries: Democratic Republic of the Congo, Gabon, Guinea, Liberia, Mali, Nigeria, Republic of Congo, Sierra Leone, Sudan and Uganda. Although it is generally rare, it is often fatal, with death rates ranging from 25 to 90% in past outbreaks (average case fatality rate, 50%). No treatment or vaccine is currently approved, but there are several promising vaccines and treatments under development.
In this webinar, industry veterans Michelle Berrey, MD, MPH, and Claudia Christian discuss the importance of quality data for a successful outbreak response plan.
Outbreaks large and small require rapid, coordinated responses. In this infographic, we describe eight considerations for outbreak responses, based on the collective experience of our experts.
Outbreaks large and small require rapid, coordinated responses. In this e-book, we describe eight considerations for outbreak responses, based on the collective experience of our experts.
CHIKV outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. It was found for the first time in the Americas on islands in the Caribbean in 2013 and has spread throughout most of the Americas. It has since been identified in over 60 countries in Asia, Africa, Europe and the Americas. No commercially available vaccine to prevent or medicine to treat CHIKV infection is currently available.
Within a challenging, resource-limited setting, the project team succeeded in reaching FP/FV six weeks after arrival in Sierra Leone and 99.998% accuracy of the planned-to-execute budget.
FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.